Novo Holdings backs HST Pathways growth push

HST Pathways said Novo Holdings has made a strategic growth investment alongside Bain Capital and Nexxus Holdings to help expand its ambulatory surgery center software platform. The deal is meant to accelerate AI-enabled products, automate center operations and support growth as ASCs face tighter margins and more complex operations.

Why it matters: - HST Pathways sits in the software layer that helps ambulatory surgery centers run clinical, financial and operational workflows. - The new investment is aimed at speeding AI-enabled tools and agentic workflow capabilities that could reduce manual work and surface operational risks earlier. - ASC operators are facing pressure from flat reimbursement, rising costs, staffing and supply constraints, and more competition, making automation and connected data more valuable.

What happened: - HST Pathways announced a strategic growth investment from Novo Holdings. - Bain Capital and Nexxus Holdings are continuing as investors in the company. - The announcement was made June 5, 2026, from Nashville, Tennessee. - Novo Holdings is joining HST at a time when the company is pushing further into AI-enabled workflow products for ASCs.

The details: - HST Pathways provides cloud-based software purpose-built for ambulatory surgery centers. - The company says the investment will support its next phase of growth and product development. - HST’s roadmap includes AI-enabled products and agentic workflow capabilities. - The platform is designed to help ASCs automate manual work, identify operational risks earlier and improve visibility and efficiency. - HST describes its offering as a connected “single pane of glass” platform. - The platform unifies clinical, financial and operational workflows. - HST says the software helps centers improve patient and provider experiences and capture more revenue. - The company supports more than 1,800 customers, more than 75,000 users and 50 million cases documented across its platform. - Novo Holdings called HST a differentiated platform in one of healthcare’s fastest-growing markets. - HST said the company’s mission is to help ASCs thrive in a market where the margin for error is smaller. - David Thawley, HST chief executive officer, said the investment will support faster innovation in practical AI and agentic capabilities. - Thawley said those capabilities are intended to help centers automate manual workflows, improve OR utilization, forecast case profitability, strengthen revenue cycle performance and turn data into action sooner. - Jonathan Levy, senior partner on Novo Holdings’ Principal Investments team, said ASCs are becoming more important because they can deliver high-quality care at lower cost. - Levy said Novo Holdings believes HST is positioned to help centers manage complexity with purpose-built software, robust data and AI-enabled capabilities at scale. - Darren Abrahamson, partner at Bain Capital Tech Opportunities, said Novo Holdings adds healthcare technology expertise at a pivotal moment for HST and the ASC market. - HST and its investors said the company is well positioned to continue building its operating platform for modern ASCs. - HST’s website is more information. - Novo Holdings says it manages assets for the Novo Nordisk Foundation and had total assets of $109 billion as of year-end 2025. - Bain Capital says its Tech Opportunities business focuses on growing technology companies in large end markets. - Nexxus Holdings says it is a single-family office founded by Tim Babich and focuses on special situations and technology-driven efficiencies.

Between the lines: - The deal signals investor confidence in ASC software as outpatient surgery shifts more procedures away from hospitals. - HST is positioning AI not as a standalone product, but as a way to make operating centers more proactive and data-driven. - The message from the investors is that ASC complexity is rising, and software vendors that can connect data and automate work may gain a larger role in the market.

What’s next: - HST is expected to accelerate development of AI and agentic workflow tools. - The company will likely keep leaning on its investor base to expand product capabilities and deepen customer impact. - As more procedures move to the ASC setting, HST is betting that centers will want more precise, faster and more visible operations.

The bottom line: - HST Pathways is using fresh backing from Novo Holdings to push harder into AI-powered ASC operations software at a moment when outpatient surgery centers are under more pressure to run efficiently and profitably.